文献速递毛发、甲与色素性疾病自身免疫性与大疱性皮肤病

医疗提供者对非节段性白癜风严重程度、患者影响及治疗差距的观点:美国与欧洲六国定性研究

Healthcare Providers' Perspectives on Nonsegmental Vitiligo Severity, Patient Impact, and Treatment Gaps in the United States and Europe.
PubMed 文献 · Br J Dermatol · 2026-08-01

该研究通过半结构化访谈,调查了美国与欧洲六国65名医疗提供者(61名皮肤科医生和4名执业护士)如何评估非节段性白癜风严重程度及其对治疗决策的影响。结果显示,严重程度定义因地区而异,常依赖患者报告的生活质量、皮损范围和部位;治疗目标包括稳定疾病、复色和改善生活质量,但现有治疗存在安全性、可及性和持久性障碍。医疗提供者强调生活质量应作为严重程度评估、目标设定和治疗成功的核心。

要点

  • 非节段性白癜风严重程度定义缺乏标准化,各国有差异。
  • 生活质量是严重程度评估、治疗目标和成功判定的核心。
  • 现有治疗受安全性、可及性和持久性限制,影响长期使用。

核心结论

  • 非节段性白癜风的异质性影响医疗提供者对疾病严重程度的评估、治疗决策及治疗成功评价。
  • 在缺乏标准化严重程度标准的情况下,各国定义存在差异。
  • 医疗提供者强调生活质量是严重程度评估、目标设定和治疗成功的核心,需整合患者体验和共享决策的临床框架。

研究设计与样本

  • 对来自美国和欧洲六国的65名医疗提供者(61名皮肤科医生和4名执业护士)进行半结构化访谈。
  • 访谈涵盖疾病严重程度分类和非节段性白癜风治疗方法,采用内容分析进行主题分析。

主要发现

  • 医疗提供者报告的严重程度定义不一,常依赖患者报告的生活质量、皮损范围和皮损部位等因素。
  • 治疗目标包括疾病稳定、复色和改善生活质量。
  • 常用治疗包括外用糖皮质激素和钙调神经磷酸酶抑制剂、系统性激素、外用JAK抑制剂和光疗,但存在地区差异。
  • 治疗选择由疾病进展、皮损范围和患者负担驱动。
  • 医疗提供者指出当前治疗挑战包括可及性和依从性障碍、安全风险以及缺乏具有持久反应的长期选择。

关键数值与推荐

  • 治疗成功和失败的定义因地区而异,但包括复色和对生活质量的积极影响。

临床怎么用

  • 临床中应重视生活质量在严重程度评估、治疗目标设定和治疗成功判定中的作用。
  • 需考虑地区差异和治疗可及性、安全性及持久性限制,制定个体化治疗方案。
  • 推动共享决策,整合患者体验于非节段性白癜风全程管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-segmental vitiligo (NSV) is a heterogeneous autoimmune disease with wide clinical variability in lesion appearance, location, and disease activity. The impact of vitiligo on the patient is also complex, with clinical, treatment, and inter- and intrapersonal factors shaping the patient's perception of disease severity. Given the complexity of clinical and patient burden, there remains a critical gap in understanding how healthcare professionals integrate these factors into clinical severity assessments and how such assessments inform treatment and management decisions. OBJECTIVES: Describe how healthcare providers (HCPs) across six countries assess NSV severity and how it informs treatment and management of NSV. METHODS: Semi-structured interviews were conducted with 65 HCPs (61 dermatologists and 4 nurse practitioners) in the United States (US) and Europe. The interviews covered classifying disease severity and approaches to treating NSV. Interviews were thematically analyzed using a content analysis. RESULTS: HCPs reported variable definitions of vitiligo severity, often relying on patient-reported QOL, extent of lesions, and lesion location, among other factors. Treatment goals consisted of disease stabilization, repigmentation, and improving QOL. Topical corticosteroids and calcineurin inhibitors, systemic steroids, topical JAK inhibitors, and phototherapy are regularly used to treat NSV, but with regional differences. Treatment selection is driven disease progression, extent of lesions, and patient burden. However, HCPs noted challenges with current treatments, including access and adherence barriers, safety risks, and a lack of long-term options with durable response. Definitions of treatment success and failure varied across regions, but included repigmentation and positive impact on QOL. CONCLUSIONS: The heterogeneity of NSV shapes HCP assessments of disease severity, treatment decision-making, and evaluations of treatment success. In the absence of standardized disease severity criteria, definitions varied across countries. Although existing treatments can be effective, barriers related to safety, access, and durability limit long-term use. Across countries, HCPs emphasized QOL impacts as central to severity assessment, goal setting, and treatment success, underscoring the need for clinical frameworks that integrate the patient experience and shared decision-making in all aspects of NSV care.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kurosky SK, Adiri R, Lukic T, et al. Healthcare Providers' Perspectives on Nonsegmental Vitiligo Severity, Patient Impact, and Treatment Gaps in the United States and Europe. Br J Dermatol. 2026. PMID: 42538872. doi:10.1093/bjd/ljag309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。